نتائج البحث

1

دورية أكاديمية

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

المصدر: ONCOTARGET ; ISSN: 1949-2553

مصطلحات موضوعية: Medicine and Health Sciences, sorafenib, DISPLAYS CYTOTOXIC ACTIVITY, AFP, HGF, MET, HCC, C-MET, ARQ 197, ADULT PATIENTS, TYROSINE KINASE, SOLID TUMORS, DOUBLE-BLIND, LUNG-CANCER, BIND MET

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/8200522Test; http://hdl.handle.net/1854/LU-8200522Test; http://dx.doi.org/10.18632/oncotarget.11621Test; https://biblio.ugent.be/publication/8200522/file/8200548Test

الإتاحة: https://doi.org/10.18632/oncotarget.11621Test
https://biblio.ugent.be/publication/8200522Test
http://hdl.handle.net/1854/LU-8200522Test
https://biblio.ugent.be/publication/8200522/file/8200548Test

View record in BASE

2

دورية أكاديمية

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer

المؤلفون: Sundar, Raghav, Chenard-Poirier, Maxime, Collins, Dearbhaile Catherine, Yap, Timothy A

المساهمون: MEDICINE

المصدر: Elements

العلاقة: Sundar, Raghav, Chenard-Poirier, Maxime, Collins, Dearbhaile Catherine, Yap, Timothy A (2017-04-10). Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. FRONTIERS IN MEDICINE 4 (APR). ScholarBank@NUS Repository. https://doi.org/10.3389/fmed.2017.00039Test; https://scholarbank.nus.edu.sg/handle/10635/228507Test

الإتاحة: https://doi.org/10.3389/fmed.2017.00039Test
https://scholarbank.nus.edu.sg/handle/10635/228507Test

View record in BASE

النص الكامل

3

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

المصدر: Oncotarget, 7 (45
Oncotarget
ONCOTARGET

مصطلحات موضوعية: Oncology, Male, Phases of clinical research, TYROSINE KINASE, chemistry.chemical_compound, DOUBLE-BLIND, 0302 clinical medicine, Medicine and Health Sciences, Medicine, ADULT PATIENTS, HGF, HCC, Aged, 80 and over, Liver Neoplasms, Middle Aged, Proto-Oncogene Proteins c-met, Sorafenib, SOLID TUMORS, Pyrrolidinones, BIND MET, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Quinolines, MET, 030211 gastroenterology & hepatology, Female, medicine.drug, Research Paper, Adult, medicine.medical_specialty, C-Met, Carcinoma, Hepatocellular, AFP, Settore MED/12 - GASTROENTEROLOGIA, 03 medical and health sciences, LUNG-CANCER, Internal medicine, Biomarkers, Tumor, Humans, Tivantinib, Lung cancer, Survival analysis, Aged, business.industry, DISPLAYS CYTOTOXIC ACTIVITY, Cancer, medicine.disease, Survival Analysis, digestive system diseases, chemistry, C-MET, business, ARQ 197, Psychiatrie

وصف الملف: 1 full-text file(s): application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fce276e8e8c86655262ae08519e9654Test
http://hdl.handle.net/10807/93882Test

4

دورية أكاديمية

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

المؤلفون: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.

مصطلحات موضوعية: Triple-negative breast cancer, Tivantinib, MET, ARQ 197

وصف الملف: application/pdf

العلاقة: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608248/pdfTest/; Investigational New Drugs; Tolaney, S. M., S. Tan, H. Guo, W. Barry, E. Van Allen, N. Wagle, J. Brock, et al. 2015. “Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.” Investigational New Drugs 33 (1): 1108-1114. doi:10.1007/s10637-015-0269-8. http://dx.doi.org/10.1007/s10637-015-0269-8Test.; http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318525Test

الإتاحة: https://doi.org/10.1007/s10637-015-0269-8Test
http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318525Test

View record in BASE

النص الكامل

5

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

المؤلفون: Eberechi Sandra Agwa, Patrick C. Ma

المصدر: Cancer Management and Research

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9deda9462a597821d5d8e9891c7d1138Test
https://pubmed.ncbi.nlm.nih.gov/25328417Test

6

دورية أكاديمية

Off-Target Effects of c-MET inhibitors on Thyroid Cancer Cells

المؤلفون: Zhou, Yan, Zhao, Conghui, Gery, Sigal, Braunstein, Glenn D., Okamoto, Ryoko, Alvarez, Rocio, Miles, Steven A., Doan, Ngan B., Said, Jonathan W., Gu, Jiang, Koeffler, H. Phillip

المساهمون: Zhou, Y (reprint author), Peking Beijing Univ, Sch Basic Med Sci, Dept Pathol, Beijing, Peoples R China., Peking Univ, Sch Basic Med Sci, Dept Pathol, Beijing 100871, Peoples R China., Novogene Bioinformat Inst, Beijing, Peoples R China., Shantou Univ, Coll Med, Shantou, Peoples R China., Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA., Univ Calif Los Angeles, Med Ctr, Dept Pathol, Los Angeles, CA 90024 USA., Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore., Natl Univ Singapore, Natl Canc Inst, Singapore 117548, Singapore., Peking Beijing Univ, Sch Basic Med Sci, Dept Pathol, Beijing, Peoples R China.

المصدر: SCI

مصطلحات موضوعية: HEPATOCYTE GROWTH-FACTOR, TIVANTINIB ARQ 197, PAPILLARY CARCINOMA, CYTOTOXIC ACTIVITY, ANTITUMOR-ACTIVITY, SIGNALING PATHWAY, BREAST-CANCER, EXPRESSION, RECEPTOR, PROTEIN